Takeda
FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic for Takeda's Exkivity
Foundation Medicine said its assay is the only blood-based comprehensive genomic profiling platform to have gained this approval for Takeda's EGFR drug.
In Brief This Week: Centogene, DermTech, Nicklaus Children's Hospital, Daiichi Sankyo, AstraZeneca
News items for the week of April 10, 2023.
Adaptive Biotechnologies, Takeda Partner to Develop Treatments for Lymphoid Malignancies
The multiyear collaboration will use Adaptive's ClonoSeq assay to measure minimal residual disease status as an endpoint for Takeda’s clinical trials.
In Brief This Week: Legend Biotech, Point Biopharma, AstraZeneca, Daiichi Sankyo, Takeda, Micronoma
News items for the week of Jan. 9, 2023.
Takeda to Discuss Positive Phase III Iclusig Data in Upfront ALL With Regulators
The trial pitted Iclusig against the TKI Gleevec as first-line treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
Sep 30, 2022